Antibiotics and hospital-acquired Clostridium difficile infection: Update of systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 881-891

  Slimings, Claudia ^a   Riley, Thomas V ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Antimicrobials; Diarrhoea; Healthcare facilities; Risk factors

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SULFONAMIDE; TRIMETHOPRIM DERIVATIVE;

BIBLIOGRAPHIC DATABASE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DISEASE ASSOCIATION; DOCUMENTATION; DRUG EXPOSURE; GENETIC HETEROGENEITY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; META ANALYSIS; NEWCASTLE OTTAWA SCALE; OBSERVATIONAL STUDY; RATING SCALE; REVIEW; SYSTEMATIC REVIEW;

ANTIMICROBIALS; DIARRHOEA; HEALTHCARE FACILITIES; RISK FACTORS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; HOSPITALS; HUMANS;

EID: 84896447804     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt477     Document Type: Review

References (37)

1. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18: 282-9.
2. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-50.
3. Kuijper EJ, van den Berg RJ, Debast S et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006; 12: 827-30.
4. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
5. Lambert PJ, Dyck M, Thompson LH et al. Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 2009; 30: 945-51.
6. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
7. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. www.cochrane-handbook.org(1March2013,date last accessed).
8. Weinberg E, Quianzon E, Bangoria K et al. Clostridium difficile infection: antibiotic risk and financial impact. Am J Gastroenterol 2006; 101: S196-S.
9. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. http ://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (21 June 2013, date last accessed).
10. Brown KA, Khanafer N, Daneman N et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-32.
11. Sterne JAC. Meta-Analysis in Stata: An Updated Collection fromthe Stata Journal. Texas: StataCorp LP, 2009.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
13. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
14. Kallen AJ, Thompson A, Ristaino P et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30: 264-72.
15. Polgreen PM, Chen YY, Cavanaugh JE et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28: 212-4.
16. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29: 44-50.
17. Modena S, Bearelly D, Swartz K et al. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005; 26: 685-90.
18. Stevens VW. Antibiotic exposure and risk of Clostridium difficile infection: a retrospective cohort study. PhD Thesis. University of Rochester, 2010.
19. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006; 44: 2785-91.
20. Minson Q, Mok S. Relationship between antibiotic exposure and subsequent Clostridium difficile-associated diarrhea. Hosp Pharm2007; 42: 430-4.
21. Sundram F, Guyot A, Carboo I et al. Clostridium difficile ribotypes 027and 106: clinical outcomes and risk factors. J Hosp Infect 2009; 72: 111-8.
22. Hensgens MPM, Goorhuis A, Dekkers OM et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67: 742-8.
23. Thomas C. The epidemiology and control of Clostridium difficile infection in a Western Australian hospital. PhD Thesis. The University of Western Australia, 2003.
24. McCusker ME, Harris AD, Perencevich E et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9: 730-3.
25. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-80.
26. Vesta KS, Wells PG, Gentry CA et al. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case-control evaluation. Am J Infect Control 2005; 33: 469-72.
27. Citak M, Backhaus M, Dogan A et al. [Clostridium difficile-associated infections in a septic ward of a level 1 trauma centre: an analysis of 159 patients]. [Article in German]. Zeitschrift fur Orthopadie und Unfallchirurgie 2012; 150: 62-6.
28. Henoun Loukili N, Martinot M, Hansmann Y et al. [Risk factors for nosocomial Clostridium difficile diarrhoea in an infectious and tropical diseases department]. [Article in French]. Medecine et maladies infectieuses 2004; 34: 57-61.
29. Lee JH, Lee SY, Kim YS et al. [The incidence and clinical features of Clostridium difficile infection; single center study]. [Article in Korean]. Korean Journal of Gastroenterology= Taehan Sohwagi Hakhoe chi 2010; 55: 175-82.
30. Pareja Sierra T, Calvo MH. Epidemiological, clinical and laboratory factors related to Clostridiumdifficile-associated diarrhoea in an elderly hospitalized population. A case-control study. [Article in Spanish]. Revista Espanola de Geriatria y Gerontologia 2007; 42: 257-62.
31. Pazos R, Isusi A, Fernandez R et al. [Nosocomial diarrhea outbreak due to Clostridium difficile in a vascular surgery department]. [Article in Spanish]. Enfermedades infecciosas y microbiologia clinica 2003; 21: 237-41.
32. Vardakas KZ, Konstantelias AA, Loizidis G et al. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis 2012; 16: e768-73.
33. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
34. McDonald LC, Coignard B, Dubberke E et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-5.
35. Dial S, Kezouh A, Dascal A et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-72.
36. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
37. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Medicine 2007; 4: e296.